how is the new business working out for ya?
PLRS did run to $0.14 none-the-less. I sold it! To much dilution.
Could $0.02 cent PLRS become a $5 stock?
PLURISTEM LIFE SYS (OTC BB:PLRS.OB)
A dollar to Five? here are three stocks in stem cell line.
ASTM, STEM and VIAC as examples.
AASTROM BIOSCIENCE (NasdaqCM:ASTM) $1.37
STEMCELLS INC (NasdaqGM:STEM) $2.69
VIACELL, INC. (NasdaqGM:VIAC) $5.20
PLRS has the funding for research as they are umbilical/placenta stem cell.
Call PLRS stock pot luck if you want!
Read the letter from the borrowed post from the STEM message board. The government is not allowing stem cell research to fade away!
Borrowed from STEM message board on Yahoo.
Here is a copy of a letter that my senator sent to me today October 17, 2006. Congress is not going to let the stem cell issue drop. Companies like STEM will provide treatment to help millions of sick Americans.
Since you have contacted me in the past in support of federal funding for stem cell research, I wanted to update you on the status of this issue as the 109th Congress draws to a close.
The House of Representatives passed the Stem Cell Research Enhancement Act (H.R. 810) in May of 2005 by a substantial margin. Despite strong support in the Senate, the Majority leadership did not bring H.R. 810 to a vote in the Senate until July of 2006, at which point 66 Senators voted for
passage of the measure. I am a cosponsor of the Senate version of this bill and was encouraged by the strong vote in favor of the measure.
This bill sought to provide federal funding for stem cell research using only embryos that "would never be implanted in a woman and would otherwise be discarded." Such research has vast potential to improve treatments for dozens of serious illnesses, including multiple sclerosis, juvenile
diabetes, Lou Gehrig's disease, Parkinson's disease, and paralysis.
On July 19th of this year, the President used his power to override a majority of both houses of Congress and vetoed the Stem Cell Research Enhancement Act. It was the first veto of his presidency. Patient advocate groups and research institutions voiced their dismay that the
Administration would withhold funding for such a promising field of biomedical research. Though the House of representatives immediately took up the measure again, the bill fell short of the 290 votes needed to overcome the President's veto.
The potential to improve the lives of individuals who suffer from debilitating illness should not and cannot be ignored. That the President would choose this legislation for his first veto was a troubling message for the patients and families clinging to the hope of medical breakthroughs. I will keep working for the passage of the Stem Cell
Research Enhancement Act in the 110th Congress.
Richard J. Durbin United States Senator
Thanks for the ATWT tip...will surely look into it...
Yes, I am definitely monitoring this board and by extension, my portfolio...Do appreciate your kind words of encouragement for my new venture...it is pretty exciting stuff...hint: It has to do with drinking water, carbon credits and Kyoto Accord...
If you're still reading this board, may want to check out ATWT. This is a pinkie (reportedly incorporated that way, not downsized to a pinkie) that had a s/h meeting in Memphis this past Saturday (s/h mtg. = unusual for a pinkie?).
Two posts below give some basic insight. If interested further, web address is atwec.com.
IHUB posters of note = the 2 below (stevo51 & Scooter1), vlftraders and dmondial. Plenty more but these will give you the basics.
Current market cap = 750M shares o/s x .006/.0065 = <$5M.
Good luck to you in your new business endeavor.
Thanks for staying in touch...
Yes, you are quite right, I have been kinda quiet these past few months...
I have been very busy working on a new business opportunity...and since this portfolio has been somewhat staid and mostly treading water, I do not feel the need to monitor it too closely...hence the quietness.
However, with Fall approaching and the markets perking up, I hope to be more active with the portfolio's management during these few remaining months of the year...
Hope all is well with you too...
SELL BLLI: Filled!
1,500 shares @ $2.09 = $3135.00 - $8.99 (commission) = $3126.01
Fund's current holding in BLLI after this sale = 0 share
Fund's current Cash Position after this sale: $108.79 (from before) + $3126.01 = $3,234.80
NEW TRADE: BLLI
NUMBER OF SHARES: 1,500
Price: $2.09 (Limit) GTC
Reason for Sale: Company will be bought out by HealthPointCapital for $2.15 per share. That's too bad because I had high hopes for this stock.
DOIG under selling pressure again! Excellent entry level!
It paid me once! It may pay me again!
They are drilling! So will be volume activity!
10 wells of activity! Should play out interesting!
Think this should be good as drilling is just getting underway!
10 wells of activity. All shallow frio formations!
The last private placement was also completed at $2.20
If you thought that the stock's fundamentals were good enough for a purchase price of 23.2¢, then you should be salivating at this 20% discount opportunity afforded to you by the market's current shortsightedness...
Though I am very bullish on the company's longterm prospects, I cannot predict with certainty this stock's short term price moves...personally though, waiting for a price of 13¢ may be a bit of an overreach...jmho. Please make your investment moves based on your own personal time horizons...
Buy MOBL: Filled!
10,000 shares @ $0.195¢ = $1950.00 + $8.99 (commission) = $1958.99
Fund's current holding in MOBL: 30,000 shares (from before) + 10,000 = 40,000 shares
Fund's current Cash Position after this Buy: $2,067.78 (from before) - $1958.99 = $108.79
Thank You for the kind wishes...
I realize that I have been a bit tardy with my posts here, especially with my End of the Month reports, due mostly to some personal/family commitments...But since the portfolio has been basically marking time, I have not felt an urgent need to post these reports (compiling them is a bit time consuming)...For instance, during this past month of March, the portfolio's closing value was $40,664.49, down a mere $176.14 (-0.43%) from its February 2006 closing price of $40,840.63. However, in the month of April 2006, the portfolio took a drubbing of more than $2000 due to the recent correction/consolidation(s) in almost all of the portfolio's major components, namely PPHM, MOBL, BSIC, EZEN and CMNN...I will be posting the end of the month update soon...
With regards to MOBL and PPHM, Yes(!), I am still just as BULLISH...
SVSE still adding at the .262 and .265 levels to my previous averaged down position.
SPEX earnings be out about the second week of May 2006.
Lets just say! I just had alot of clearity in regards to what is what and who is who with this company SPEX.
InfoSpherix Division is profitable and making money. fact!
BioSpherix Division is now presently in the process of networking the clinical three trial for its diabetes drug. This is the companies main focus.
SPEX -- Tagatose as Alzheimer preventative?
SPEX getting after market hour attention. I rarely see any after hour activity on SPEX. $2.59
NATURLOSE (Tagatose) & DIABETES
Tagatose as Alzheimer preventative
Long-Term Sentiment: Strong Buy 05/01/06 06:38 pm
Msg: 109681 of 109681
According to a recent article. Diabetes drug may help ward off alzheimer disease. Alzheimer is being found to be secondary to Diabetes type two. I am being only suggestive with my personal opinion of the following. It makes sense that it is very highly likely that Tagatose may also ward off alzheimers. read the article. (link)
Alzheimer's patients put diabetes pill to the test
New theory suggests diabetes drug could help slow brain decay
Alzheimer's patients put diabetes pill to the test
New theory suggests diabetes drug could help slow brain decay
Updated: 5:35 p.m. ET May 1, 2006
WASHINGTON - A provocative new theory suggests that one root cause of Alzheimer’s disease is linked to diabetes — a theory about to be tested in thousands of Alzheimer’s patients given the diabetes drug Avandia in hopes of slowing brain decay.
It’s a scary scenario: Alzheimer’s already is expected to skyrocket as the population grays, rising from 4.5 million sufferers today to a staggering 14 million by 2050. If the new theory is right, the nation’s current obesity-fueled epidemic of Type 2 diabetes could worsen that toll.
But proponents see potential good news: If diabetic-like changes in the way brain cells use sugar to generate energy truly trigger Alzheimer’s in at least some patients, then maybe doctors could intervene early and slow down that degeneration.
A preliminary experiment involving 511 Alzheimer’s patients found signals that Avandia might help — albeit in people who lack a gene that spurs more aggressive Alzheimer’s.
Those results, combined with other evidence that the diabetes pathway is important, have Avandia maker GlaxoSmithKline poised to open three Phase III clinical trials this summer to test whether the diabetes drug, also called rosiglitazone, might protect certain patients’ brains.
Diabetes has long been listed a risk factor for Alzheimer’s later in life because it damages blood vessels that supply the brain.
The Avandia research suggests a more insidious connection: that Alzheimer’s can be silently triggered when brain cells can’t properly use their main fuel, sugar — just as Type 2 diabetes is triggered when insulin gradually loses its ability to process sugar body-wide.
“When they’re in an insulin-resistant state, it does not just affect the body, it affects the brain as well,” explains Suzanne Craft of the Veterans Affairs Puget Sound Health Care System, who led the initial research.
There are 18 million Type 2 diabetics, considered to have two to five times a non-diabetic’s risk of developing Alzheimer’s — if they live long enough, into the 60s and 70s when Alzheimer’s typically strikes, Craft says. Type 2 diabetes often leads to heart disease or other ailments that kill before then.
Avandia, and the competing drug Actos, treat Type 2 diabetes by resensitizing the body to insulin.
Don’t use Avandia for Alzheimer’s until that question is settled, cautions Glaxo’s Allen Roses, a highly regarded Alzheimer’s researcher who, before joining the pharmaceutical company, discovered the brain disease’s main genetic link.
He published the diabetes hypothesis in the medical journal Alzheimer’s & Dementia last week.
If it pans out, “one thing we can do is, possibly, slow down the onset of the disease showing up,” Roses says. But for now, “it’s a hopeful experiment that’s in progress.”
Yet it’s generating intense interest.
“This is an exciting new approach,” Yadong Huang of the University of California, San Francisco, wrote in an accompanying review of Roses’ hypothesis, which is backed by genetics research from Huang’s own lab.
“I don’t think this is hype for rosiglitazone,” adds Dr. Sam Gandy, director of the Farber Institute for Neurosciences at Philadelphia’s Thomas Jefferson University and an Alzheimer’s Association spokesman. “This does dovetail with some existing knowledge.”
Alzheimer's is a degenerative brain disease that usually begins gradually, causing a person to forget recent events or familiar tasks. How rapidly it advances varies from person to person, but the disease eventually leads to confusion, personality and behavior changes and impaired judgment. Communication becomes more difficult as the disease progresses, leaving those affected struggling to find words, finish thoughts or follow directions. Eventually, most people with Alzheimer's disease become unable to care for themselves.
Source: Alzheimer's Association • Print this
Cells underuse sugar
No one knows what causes Alzheimer’s creeping brain degeneration. Today’s drugs only temporarily help symptoms. Now, researchers are hunting new ones that target the disease’s hallmark, a sticky gunk called beta-amyloid that clogs up, and probably kills, neurons.
The new theory: The metabolism of neurons’ internal power factors, called mitochondria, go awry so that those cells don’t use enough sugar. That eventually leads to impaired brain cell function, including the buildup of that gunky beta-amyloid. It also means that neurons in youth and middle age don’t sprout enough communication connections, providing less “cognitive reserve” once their neurons start dying off.
Among the evidence Roses cites:
Decades before dementia symptoms begin, PET scans of people who carry an Alzheimer’s-linked gene show their brain cells underuse sugar.
Mice engineered to develop Alzheimer’s-like disease experience the metabolism changes before beta-amyloid plaques appear — and insulin-sensitizing drugs enhance their brains’ sugar use.
Researchers who tracked 140,000 diabetic veterans found those who received insulin-resensitizing drugs were less likely to be diagnosed with Alzheimer’s years later.
Then there’s that preliminary Avandia study. Alzheimer’s patients showed modest improvement in cognitive function — unless they carried the Alzheimer’s-linked gene called ApoE4 that spurs more aggressive disease. The new studies will try to prove if that benefit was real.
© 2006 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed
SELL SLXI: Filled!
1,000 shares @ $0.085 = $85.00 - $8.99 (commission) = $76.01
Fund's current holding in SLXI after this sale = 0 share
Fund's current Cash Position after this sale: $1,991.77 (from before) + $76.01 = $2,067.78
SELL PRRPF: Filled!
1,000 shares @ $0.152 = $152.00 - $8.99 (commission) = $143.01
Fund's current holding in PRRPF after this sale = 0 share
Fund's current Cash Position after this sale: $1,848.76 (from before) + $143.01 = $1,991.77
SVSE starter position at .34, oil/gas play
this is actually excellent news.
I would tend to belive this company is close to showing some revenues turning to profits.
disclaimer; I own a small starter position
Also I have also been buying SPEX.
SPEX on severe watch list. some short notes.
It has backed off about 30% from its recent run on news. $3.70
it is off its 52 week high of $5.85. present price is discounted 55% sitting at $2.65
This Company's backlog is a new recorded level of $72 million.
Commercial clients who have used SPEX Healthcare Business Solutions include:
Abbott Laboratories Johnson & Johnson
Astra Pharmaceuticals Merck
Aventis Pharmaceuticals Novo Nordisk
Berlex Laboratories Ortho Biotech
Bristol-Myers Squibb Pfizer
Elan Pharmaceuticals Roche Laboratories
Eli Lilly Schering Plough
The real big news is underway in regards to Phase three of its diabetic treatment.
The company is also a big reservation contractor for the camping industry.
***End Of The Month Summary: February 2006***
Detailed below is the Contax’s Five & Dime Fund’s performance
versus the benchmark S&P 500, for the month of February 2006:
Current (2/28/2006) Value of the S&P 500 Index: 1,280.66
Closing value of the S&P 500 Index on January 31st. 2006: 1,280.08
Change for the Month of February 2006: + 0.58
Percentage Change in the S&P 500 Index for the month of February 2006: + 0.05%
Value of the S&P 500 Index at the time of Inception
of the CFDTDF Fund (November 9th. 2003): 1,053.21
Value of the S&P 500 Index on January 1st 2006: 1,248.29
Percentage Change in the S&P 500 Index since the Fund's Inception: + 21.59%
Percentage Change in the S&P 500 Index Year-To-Date (YTD): 2.59%
This Month’s Closing Summary of CFDTDF Fund:
Current (2/28/2006) Net Asset Value (NAV): $40,840.63
Closing value of the Fund on January 31st 2006: $41,061.50
Change for the Month of February 2006: - $220.87
Percentage Change during February 2006: - 0.54%
Net Asset Value at the time of the Fund's Inception: $20,000
Net Asset Value on January 1st. 2006: $ 35,343.93
Percentage Change of NAV Year-to-Date (2/28/2006): + 15.55%
Percentage Change of NAV since the Fund’s inception: + 104.20%
Fund’s Performance versus the S&P since the Fund’s Inception: + 82.61%
Fund's Performance YTD versus the S&P 500: + 12.96%
The following, is the Contax's Five & Dime and Two $$ Too Investment Fund’s (CFDTDF)
current stock holdings along with their end of the month closing price(s):
Updated position(s) of the Fund as of February 28th 2006:
1) PPHM: 6,800 shares Valued at $9,520.00 (February 28th 2006 Closing Price: $1.40)
2) MOBL: 30,000 shares Valued at $7,680.00 (February 28th 2006 Closing Price: $0.256¢)
3) BSIC: 2,500 shares Valued at $6,000.00 (February 28th 2006 Closing Price: $2.40)
4) CMNN: 4000 shares Valued at $4,800.00 (February 28th 2006 Closing Price: $1.20)
5) EZEN: 1,000 shares Valued at $3,300.00 (February 28th 2006 Closing Price: $3.30)
6) BLLI: 1,500 shares Valued at $2,775 (February 28th 2006 Closing Price: $1.85)
7) WSCE: 3,000 shares Valued at $2,400 (February 28th 2006 Closing Price: $0.80¢)
8) PRRPF: 6,000 shares Valued at $1,080.00 (February 28th 2006 Closing Price: $0.18¢)
9) BIPH: 517 shares Valued at $847.88 (February 28th 2006 Closing Price: $1.64)
10) NEOM: 2,000 shares Valued at $780.00 (February 28th 2006 Closing Price: $0.39¢)
11) PHPG: 400 shares Valued at $640.00 (February 28th 2006 Closing Price: $1.60)
12) ADVR: 1,000 shares Valued at $65.00 (February 28th 2006 Closing Price: $0.065¢)
13) SLXI: 1,000 shares Valued at $50.00 (February 28th 2006 Closing Price: $0.05¢)
14) $Cash$ on February 28th 2006: $902.75
The current holding(s) as a percentage of the CFDTDF Fund's
Net Asset Value (NAV) as of February 28th 2006 is as follows:
1) PPHM = 23.31%
2) MOBL = 18.80%
3) BSIC = 14.69%
4) CMNN = 11.75%
5) EZEN = 8.08%
6) BLLI = 6.80%
7) WSCE = 5.88%
8) PRRPF = 2.64%
9) BIPH = 2.08%
10) NEOM = 1.91%
11) PHPG = 1.57%
12) ADVR = 0.16%
13) SLXI = 0.12%
14) $Cash$: 2.21%
The Current (2/28/2006) NAV of the Fund is $40,840.63
Present (2/28/2006) cash position of the Fund: $ 902.75
As of the end of February 28th 2006, the total percentage of the NAV invested: 97.79%
For the month of February 2006, the CFDTD Fund essentially marked time...
While the S&P 500 eked out with a very tiny gain of 0.05%, my Fund, on the
other hand, declined by 0.54%. Even though this decline in Dollar terms
was extremely modest, but when compared, in percentage terms, to the S&P’s
gain, this drop was anything but small…And in spite of this, I am anything but
worried about the Fund’s chances for the remainder of this year. As a matter of
fact, I am quite bullish about its prospects because I am very optimistic that its top
5 holdings, namely, PPHM, MOBL, CMNN, BSIC and EZEN, which cumulatively
constitute over 76% of the Fund’s Net Asset Value, will all make very Big moves
P.S. Due to other pressing commitments, this End of the Month report was delayed...I hope to do better with the report for the just ended month of March...
BOSTON LIFE SCIENCES (NasdaqSC:BLSI)
Looking forward. I claim a nice 3rd quarter run (sept06), prior to earnings. Earnings are insignificant. As to earnings will be a cost saving announcement that coat-tails from the accepted graduation of the phase 1 trial from the FDA. oddly this company has already passed the three phase test for this study of its Parkinsons disease and the FDA has it doing it again. So America is dieing waiting for an imaging tool to help give a better grade of life to thousands. Keeping people hopefull, but generally ending up dieing before new testing developments are allowed on the general public.
Keep it under your accumulation list.
BOSTON LIFE SCIENCES (NasdaqSC:BLSI)
accumulate for that 3rd Q,based on this statement (IMPORTANT)(parkinsons/movement disease imaging tool)
I received a return call from the company yesterday. I actually have no questions. Just making sure someone had a real voice before I toy more of their playground. Just hearing the voice! Sincerity was instilled.
Nearly 3.3 million Americans age 19 and younger used an ADHD drug last year. The company is also in clinicals for ADHD
123 I-Based imaging agent for the objective diagnosis of Attention Deficit Hyperactivity Disorder (ADHD)
The headlines tonight are all about ADHD drugs being softened for their labeling. These same headlines or similiar will return periodically. No one knows truely what to do.
New York Times article added to post
Sorry Contax! I am heart broken over my years long due diligence into prrpf. I am moving more into BSIC as time and dips allow. My last batches of buys in BSIC were at $2.18 some time ago. I have tried several times to pick up some of them low end dips, but they have eluded me.
I truely am devastated by the activities of prrpf. Its a traders stock. I simply am not a short end trader. I do believe within my self and my best judgement. If prrpf/psh do become real. It can be bought back.
SELL PRRPF: Filled!
5,000 shares @ $0.191 = $955.00 - $8.99 (commission) = $946.01
Fund's current holding in PRRPF after this sale = 1,000 shares
Fund's current Cash Position after this sale: $902.75 (from before) + $946.01 = $1,848.76
In Reply To 'contax'
This stock Prrpf is going down. There is nothing pushing this stock after the news today. It will drift back slowly again. This is not the NYSE. Take some profits and secure your position.
PRZ is actually an easy pick at this level.
Forward guidance "Year end results for 2006 are expected to show $100-$103 million in revenues; $37-$38 million in operating income; $20-$21 million in net income; and approximately $0.30-$0.31 earnings per fully diluted share"
One reason being! Wesley Franklin is with PRRPF
TOUCHSTONE RESOURCES USA, INC.
QUARTERLY REPORT ON FORM 10-QSB SEPTEMBER 30, 2005
Item 5. Other Information
On November 5, 2005, Wesley Franklin tendered his resignation as a Director